Scientific Articles
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study
Hiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, Yasuhiro Okumura, Toshimi Takano, Eriko Tokunaga, Tsuyoshi Saito, Yasuaki Sagara, Kosuke Yamazaki, Yoshihiro Kawaguchi, Tecchuu Lee, Shinji Ozaki, Kazuhiko Yamagami, Naohito Yamamoto, Katsumasa Kuroi, Hirofumi Suwa, Shoichiro Ohtani, Toshikazu Ito, Shinji Yasuno, Satoshi Morita, Shinji Ohno and Masakazu Toi; On behalf of the JBCRG-C02 Collaborative Group
Breast Cancer: Basic and Clinical Research. 2018; 12: 1-7.
https://doi.org/10.1177/1178223418786243
Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial
Norikazu Masuda, Masakazu Toi, Naohito Yamamoto, Hiroji Iwata, Katsumasa Kuroi, Hiroko Bando, Shoichiro Ohtani, Toshimi Takano, Kenichi Inoue, Yasuhiro Yanagita, Hiroi Kasai, Satoshi Morita, Takashi Sakurai and Shinji Ohno
Breast Cancer. 2018 Jul; 25(4): 407-415.
https://doi.org/10.1007/s12282-018-0839-7
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: a multicenter, open-label, phase II study Short title: Tailored neoadjuvant therapy for breast cancer
Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi
Cancer Medicine. 2018 Jun; 7(7): 3044-3056. Online ahead of print.
https://doi.org/10.1002/cam4.1600
A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells
Takayuki Ueno, Norikazu Masuda, Shunji Kamigaki, Takashi Morimoto, Futoshi Akiyama, Masafumi Kurosumi, Hitoshi Tsuda, Yoshiki Mikami, Sunao Tanaka, Satoshi Morita & Masakazu Toi
Cancer Medicine. 2018 Jun; 7(6): 2442-2451. Epub 2018 May 7.
https://doi.org/10.1002/cam4.1516
Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.
Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno
Current Medical Research and Opinion. 2018 Jan; 34(1): 49-54.
https://doi.org/10.1080/03007995.2017.1400426
A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study)
Hiroshi Ishiguro, Shigehira Saji, Shogo Nomura, Sunao Tanaka, Takayuki Ueno, Masahide Onoue, Hiroji Iwata, Takeharu Yamanaka, Yasutsuna Sasaki, Masakazu Toi
Cancer Medicine. 2017 Dec; 6(12): 2909-2917.
https://doi.org/10.1002/cam4.1258
Effectiveness of Fulvestrant in Advanced or Metastatic Breast Cancer Patients in the Real World: A Retrospective Multi-center Cohort Study with 1072 Patients (JBCRG-C06; Safari)
Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Yutaka Yamamoto, Shinji Ohno and Masakazu Toi
Breast Cancer Research and Treatment. 2017 Jun; 163(3): 545-554. Epub 2017 Mar 23.
https://doi.org/10.1007/s10549-017-4212-x
Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients (JBCRG-C01)
Hiroyasu Yamshiro · Hiroji Iwata · Norikazu Masuda · Naohito Yamamoto · Reiki Nishimura · Shoichiro Ohtani · Nobuaki Sato · Masato Takahashi · Takako Kamio · Kosuke Yamazaki · Tsuyoshi Saito · Makoto Kato · Tecchuu Lee · Shinji Ohno · Katsumasa Kuroi · Toshimi Takano · Masahiro Takada · Shinji Yasuno · Satoshi Morita · Masakazu Toi
International Journal of Clinical Oncology. 2015 Aug; 20(4): 709-722.
https://doi.org/10.1007/s10147-015-0785-8
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer
Norikazu Masuda, Kenji Higaki, Toshimi Takano, Nobuki Matsunami, Takashi Morimoto, Shoichiro Ohtani, Makiko Mizutani, Takeshi Miyamoto, Katsumasa Kuroi, Shinji Ohno, Satoshi Morita, Masakazu Toi
Cancer Chemotherapy and Pharmacology. 2014 Aug; 74(2): 229-38.
https://doi.org/10.1007/s00280-014-2492-y
Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study)
Masahiro Takada, Hiroshi Ishiguro, Shigenori Nagai, Shoichiro Ohtani, Hidetaka Kawabata, Yasuhiro Yanagita, Yasuo Hozumi, Chikako Shimizu, Shintaro Takao, Nobuaki Sato, Yoshimasa Kosaka, Yasuaki Sagara, Hiroji Iwata, Shinji Ohno, Katumasa Kuroi, Norikazu Masuda, Hiroyasu Yamashiro, Masahiro Sugimoto, Masahide Kondo, Yoichi Naito, Hironobu Sasano, Takashi Inamoto, Satoshi Morita & Masakazu Toi on behalf of the JBCRG-C03 Collaborative Group
Breast Cancer Research and Treatment. 2014 May; 145(1): 143-53.
https://doi.org/10.1007/s10549-014-2907-9
by Voluntary Organization JBCRG